← All Guides

How to Pitch a Biotech Startup

Biotech pitching follows different rules than software. Investors evaluate scientific risk, regulatory pathways, and intellectual property strength before looking at business metrics. The best biotech pitches clearly articulate the unmet medical need, the mechanism of action, and a capital-efficient path through clinical development with well-defined milestones.

Biotech funding remains robust for companies with strong scientific foundations and clear regulatory pathways. AI-driven drug discovery is attracting significant capital, but investors increasingly demand wet-lab validation alongside computational predictions. Rare diseases, oncology, and neurology continue to command premium valuations. Platform companies (applying one technology to multiple indications) are preferred over single-asset companies.

What Investors Look For

  • Strong intellectual property: patents filed, freedom-to-operate analysis, and composition of matter claims
  • A well-defined regulatory pathway with clear Phase I/II/III milestones and timelines
  • Preclinical data that de-risks the mechanism of action — not just efficacy, but safety signals
  • A capital-efficient clinical development plan that reaches meaningful milestones before the next raise
  • A founding team with drug development experience — especially navigating clinical trials
  • Large addressable patient population with significant unmet medical need and willingness to pay (or payer coverage)

Common Mistakes

  • Showing preclinical results without acknowledging the attrition rates from preclinical to approval (~90% fail)
  • Underestimating clinical trial costs and timelines — Phase II alone can cost $10-50M
  • Weak IP strategy: relying on trade secrets instead of robust patent portfolios
  • Not having a clear regulatory strategy for your specific indication and molecule type
  • Ignoring the competitive landscape of other therapies in the same indication

Key Metrics to Highlight

  • Preclinical efficacy and safety data (with statistical significance)
  • IP portfolio strength: patents granted, pending, and expiry dates
  • Clinical development timeline with capital requirements per phase
  • Addressable patient population and annual treatment cost
  • Competitive landscape positioning (efficacy, safety, convenience vs. alternatives)

Sample Investor Questions

  1. What is your mechanism of action, and what preclinical evidence supports it?
  2. Walk me through your IP portfolio — what patents are granted, pending, and what is your freedom-to-operate position?
  3. What are the key clinical development milestones and what funding does each require?
  4. What is the competitive landscape in this indication, and what is your differentiation?
  5. What is your regulatory strategy — which endpoint will the FDA accept for approval?
  6. What are the most likely failure modes, and how have you de-risked them?

FAQ

When should a biotech startup raise venture capital?

After you have preclinical proof-of-concept data and a filed patent. Many biotech founders bootstrap through grants (NIH SBIR/STTR, state programs) to reach this stage. Venture capital is typically needed for IND-enabling studies and Phase I clinical trials. Coming to investors with data dramatically improves your valuation and negotiating position.

How important is the founding team background?

Critical — more than any other sector. Biotech investors expect PhD-level scientific expertise and clinical development experience on the team. If the founders are purely scientific, investors will want to see experienced biotech operators (VP Clinical, VP Regulatory) in advisory or early hire roles. Drug development is too complex and regulated for first-timers to learn on the job.

Platform company or single asset — which is more investable?

Platform companies (one technology, multiple indications) generally receive higher valuations because they offer multiple shots on goal. However, you still need one lead indication with strong data. The best approach: pitch the lead asset as your primary value driver, then show how the platform enables a pipeline of additional programs with de-risked biology.

Ready to practice your biotech pitch with an AI investor partner?

Apply Now